0000105770-24-000035.txt : 20240426 0000105770-24-000035.hdr.sgml : 20240426 20240426161616 ACCESSION NUMBER: 0000105770-24-000035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240423 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 24884002 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 8-K 1 wst-20240423.htm 8-K wst-20240423
0000105770false00001057702024-04-232024-04-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – April 23, 2024
wstlogoq319.jpg
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania
1-8036
23-1210010
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
530 Herman O. West Drive, Exton, PA
19341-1147
(Address of principal executive offices)
(Zip Code)
 Registrant’s telephone number, including area code: 610-594-2900
Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointments of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 26, 2024, West Pharmaceutical Services, Inc. (“West”) announced an update to the role of Bernard Birkett, Chief Financial and Operations Officer. Since May 2022, Mr. Birkett served as both our Principal Financial and Principal Operating Officer. Mr. Birkett‘s leadership while in this combined role has greatly enhanced the operations capabilities of both our Proprietary Products and Contract Manufacturing Business Segments. This now allows us to transfer much of our operational leadership and decision-making to each of our Business Segments to further improve our efficiency. Effective May 1, 2024, Mr. Birkett’s title will be solely Chief Financial Officer (“CFO”), where he will retain financial oversight for both Business Segments, operational oversight of our strategic sourcing function and be involved in key operational issues together with other members of our executive team. However, we will no longer have a single principal operating officer.

Item 5.07 Submission of Matters to a Vote of Security Holders.

Our 2024 Annual Meeting of Shareholders was held virtually on April 23, 2024.

Our shareholders voted on five proposals at the Annual Meeting. After the Proxy publication date, the U.S. Securities and Exchange Commission ("SEC") issued a No-Action Letter in our favor regarding the shareholder proposal included in the Proxy as Proposal 6. Therefore, that proposal was not presented at the 2024 Annual Shareholder Meeting, because it was duplicative of management Proposals 3 and 4. The proposals are described in detail in our proxy statement dated March 13, 2024. As of February 28, 2024, the record date, there were 73,205,367 shares of our common stock outstanding. Shareholders representing 67,175,691 or 91.76%, of the common shares outstanding were present virtually or were represented by proxy at the Annual Meeting. The final results for the votes on each proposal are set forth below.

Proposal 1: Our shareholders elected the following directors to serve on our Board until the 2025 Annual Meeting of Shareholders by the following vote:

NameForAgainstAbstainBroker Non-Votes
Mark A. Buthman64,065,422781,915124,2062,204,148
William F. Feehery62,874,5251,981,149115,8692,204,148
Robert F. Friel61,754,3573,100,948116,2382,204,148
Eric M. Green59,690,6492,700,6412,580,2532,204,148
Thomas W. Hofmann60,144,4704,674,914152,1592,204,148
Molly E. Joseph64,459,745457,58454,2142,204,148
Deborah L. V. Keller53,932,2348,407,0562,632,2532,204,148
Myla P. Lai-Goldman64,413,765520,16337,6152,204,148
Stephen H. Lockhart64,631,871215,445124,2272,204,148
Douglas A. Michels60,971,8173,883,389116,3372,204,148
Paolo Pucci59,965,0054,889,598116,9402,204,148

Proposal 2: Our shareholders approved, on an advisory basis, our named executive officer compensation by the following vote:

ForAgainstAbstainBroker Non-Votes
61,974,3152,926,26370,9652,204,148

Proposal 3: Our shareholders approved to amend and restate our articles of incorporation to eliminate the supermajority transaction requirement by the following vote:

ForAgainstAbstainBroker Non-Votes
64,521,017434,65315,8732,204,148

Proposal 4: Our shareholders approved to amend and restate our articles of incorporation to eliminate the supermajority amendment requirement by the following vote:

2

ForAgainstAbstainBroker Non-Votes
64,516,512423,86731,1642,204,148

Proposal 5: Our shareholders ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2024 fiscal year by the following vote:

ForAgainstAbstain
61,537,5115,501,551136,629







Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit No.
Description
 104
The cover page from the Company’s Current Report on Form 8-K, dated April 23, 2024, formatted in Inline XBRL.



3




SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


WEST PHARMACEUTICAL SERVICES, INC.
/s/ Chad R. Winters
Chad R. Winters
Vice President, Chief Accounting Officer
April 26, 2024



4





EXHIBIT INDEX

Exhibit No.
Description
104
The cover page from the Company’s Current Report on Form 8-K, dated April 23, 2024, formatted in Inline XBRL.
5
 EX-101.SCH 2 wst-20240423.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 wst-20240423_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 4 wst-20240423_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 5 wst-20240423_g1.jpg GRAPHIC begin 644 wst-20240423_g1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page
Apr. 23, 2024
Cover [Abstract]  
Entity Central Index Key 0000105770
Document Type 8-K
Document Period End Date Apr. 23, 2024
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.
Entity Incorporation, State or Country Code PA
Entity File Number 1-8036
Entity Tax Identification Number 23-1210010
Entity Address, Address Line One 530 Herman O. West Drive
Entity Address, City or Town Exton
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19341-1147
City Area Code 610
Local Phone Number 594-2900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.25 per share
Trading Symbol WST
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.westpharma.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports wst-20240423.htm wst-20240423.xsd wst-20240423_lab.xml wst-20240423_pre.xml wst-20240423_g1.jpg http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "wst-20240423.htm": { "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20240423", "dts": { "inline": { "local": [ "wst-20240423.htm" ] }, "schema": { "local": [ "wst-20240423.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "wst-20240423_lab.xml" ] }, "presentationLink": { "local": [ "wst-20240423_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.westpharma.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20240423.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20240423.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000105770-24-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-24-000035-xbrl.zip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end XML 17 wst-20240423_htm.xml IDEA: XBRL DOCUMENT 0000105770 2024-04-23 2024-04-23 0000105770 false 8-K 2024-04-23 WEST PHARMACEUTICAL SERVICES, INC. PA 1-8036 23-1210010 530 Herman O. West Drive Exton PA 19341-1147 610 594-2900 false false false false Common Stock, par value $0.25 per share WST NYSE false